Tags : HR

AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at

Shots: AstraZeneca will divulge new developments across BC at the 2020 SABCS. The key abstract includes data of P-ll DESTINY-Breast01 study reinforcing the efficacy seen with Enhertu in HER2+ mBC following 2+ prior anti-HER2 based regimens The company will present data of P-I SERENA-1 study demonstrating the efficacy & safety of AZD9833 as a monothx. […]Read More

Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH

Shots: The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+, HER2- metastatic breast cancer whose cancer progressed following endocrine therapy The P-III MONARCH 2 study resulted in meetings 2EP of overall survival with no new observed safety […]Read More

Knight Therapeutics’ Nerlynx (neratinib) Receives Health Canada Approval as Extended

Shots: The marketing authorization is based on P-III ExteNET study results assessing Nerlynx following adjuvant trastuzumab therapy vs PBO in 2,840 patients with early-stage HER2-positive breast cancer within two of completing trastuzumab-based adjuvant therapy The P-III ExteNET study resulted in a 51% reduction in risk of diseases recurrence in patients @2yrs. with invasive disease-free survival […]Read More